Tests brentuximab with PD-1 blockade for relapsed Hodgkin lymphoma
Tests brentuximab with PD-1 blockade, then stem cell transplant, in people with returned Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Key facts
- Where
- León, MexicoSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose Hodgkin lymphoma came back or did not respond to ABVD treatment and is considered high risk.
- Age
- 18 to 90 years
- Sex
- Women and men can join.
- Disease stage
- Hodgkin lymphoma that came back or did not respond to ABVD, with a high-risk definition.
- Earlier treatment
- Earlier ABVD treatment that did not work or after which the lymphoma came back.
Main reasons for not taking part
- Taking back your own consent to join the study
- Severe (grade 3 or 4) side effects during the trial
- Loss of follow-up
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 90 years old?
Source: NCT05595447, who can take part
Where in Mexico
- Hospital Regional Alta Especialidad BajioLeón, MexicoContact: Lauro F Amador, ResearcherTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Regional de Alta Especialidad del Bajio
- Trial code
- NCT05595447
- Record updated
- 12 March 2025
- Original description
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.Read full original descriptionShow less
Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade
1?
Inclusion: Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk; Age ≥ 18 years and ≤ 90 years; Adequate liver function, defined as:; Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN; Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN; Adequate renal functions, defined as:; Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min; ECOG performance status ≤ 3; Women of reproductive potential should have a serum pregnancy test or negative urine; Prior signature of the informed consent.
Exclusion: Voluntary withdrawal from the study; Develop grade 3 or 4 toxicity according to the INH scale; Loss of follow-up.